Earnings Releases·Nov 5, 2026, 4:08 PM ET

Tandem Diabetes Care — Third Quarter 2026 Earnings Summary

Worldwide sales increased 14% year-over-year to $283.7 million, driven by 26% international growth, while gross margin expanded 270 basis points to 57% and operating loss narrowed significantly to $2.4 million from $22.9 million in the prior year.
Net loss decreased to $7.1 million and Adjusted EBITDA improved to $18.0 million, supported by a 19% year-over-year increase in U.S. supplies sales and the expansion of the pay-as-you-go reimbursement model to 15% of U.S. pharmacy channel sales.
The company reaffirmed full-year 2026 sales guidance of $1.065 billion to $1.085 billion, with estimated gross margins of 56% to 57% and Adjusted EBITDA margins of 5% to 6%.
Strategic expansion included the announcement of Tandem Mobi availability in 12 new countries and t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor in 11 international markets, while cash and short-term investments rose to $443.1 million.